Shilpa Medicare Past Earnings Performance
Past criteria checks 0/6
Shilpa Medicare's earnings have been declining at an average annual rate of -42.8%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 8.3% per year.
Key information
-42.8%
Earnings growth rate
-43.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 8.3% |
| Return on equity | -0.03% |
| Net Margin | -0.06% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Shilpa Medicare makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 11,248 | -7 | 2,978 | 0 |
| 30 Sep 23 | 11,008 | -119 | 2,973 | 0 |
| 30 Jun 23 | 10,491 | -321 | 2,873 | 0 |
| 31 Mar 23 | 10,517 | -325 | 2,977 | 0 |
| 31 Dec 22 | 11,286 | 51 | 3,063 | 0 |
| 30 Sep 22 | 11,384 | 213 | 3,054 | 0 |
| 30 Jun 22 | 11,693 | 599 | 2,795 | 0 |
| 31 Mar 22 | 11,469 | 607 | 2,824 | 0 |
| 31 Dec 21 | 10,135 | 395 | 2,692 | 0 |
| 30 Sep 21 | 9,324 | 376 | 2,612 | 0 |
| 30 Jun 21 | 9,156 | 631 | 2,404 | 0 |
| 31 Mar 21 | 9,016 | 1,478 | 2,473 | 0 |
| 31 Dec 20 | 9,135 | 1,739 | 2,281 | 0 |
| 30 Sep 20 | 9,591 | 2,213 | 2,168 | 0 |
| 30 Jun 20 | 9,698 | 2,267 | 2,027 | 0 |
| 31 Mar 20 | 9,082 | 1,562 | 2,043 | 0 |
| 31 Dec 19 | 8,876 | 1,455 | 2,022 | 0 |
| 30 Sep 19 | 8,241 | 1,029 | 1,983 | 0 |
| 30 Jun 19 | 6,962 | 944 | 1,826 | 0 |
| 31 Mar 19 | 7,337 | 1,123 | 1,834 | 0 |
| 31 Dec 18 | 7,693 | 1,193 | 1,776 | 0 |
| 30 Sep 18 | 7,814 | 1,281 | 1,704 | 0 |
| 30 Jun 18 | 8,211 | 1,167 | 1,566 | 0 |
| 31 Mar 18 | 7,894 | 1,052 | 1,555 | 0 |
| 31 Dec 17 | 7,756 | 1,133 | 1,498 | 0 |
| 30 Sep 17 | 7,731 | 1,149 | 1,422 | 0 |
| 30 Jun 17 | 7,787 | 1,190 | 1,319 | 0 |
| 31 Mar 17 | 7,795 | 1,076 | 1,330 | 0 |
| 31 Dec 16 | 7,565 | 1,048 | 1,158 | 0 |
| 30 Sep 16 | 7,735 | 1,153 | 1,092 | 0 |
| 30 Jun 16 | 7,369 | 1,024 | 1,007 | 0 |
| 31 Mar 16 | 7,166 | 1,083 | 934 | 0 |
| 31 Dec 15 | 6,867 | 886 | 1,170 | 159 |
| 30 Sep 15 | 6,430 | 776 | 1,113 | 159 |
| 30 Jun 15 | 6,234 | 728 | 844 | 0 |
| 31 Mar 15 | 6,138 | 737 | 855 | 0 |
| 31 Dec 14 | 6,145 | 731 | 997 | 95 |
| 30 Sep 14 | 6,143 | 798 | 991 | 95 |
| 30 Jun 14 | 5,966 | 787 | 723 | 0 |
| 31 Mar 14 | 5,714 | 757 | 913 | 95 |
| 31 Dec 13 | 5,025 | 664 | 767 | 46 |
| 30 Sep 13 | 4,422 | 556 | 694 | 46 |
| 30 Jun 13 | 3,965 | 536 | 645 | 46 |
Quality Earnings: 530549 is currently unprofitable.
Growing Profit Margin: 530549 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 530549 is unprofitable, and losses have increased over the past 5 years at a rate of 42.8% per year.
Accelerating Growth: Unable to compare 530549's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 530549 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.1%).
Return on Equity
High ROE: 530549 has a negative Return on Equity (-0.034%), as it is currently unprofitable.